The Role of Inflammation in Neurological Disorders: a Brief Overview of Multiple Sclerosis, Alzheimer's, and Parkinson's Disease'

Overview

Journal Front Neurol

Specialty Neurology

Date 2024 Nov 14

PMID 39539666

Authors

Yahveth Cantero-Fortiz

Merce Boada

Affiliations

Soon will be listed here.

Abstract

Neuroinflammation is a central feature in the pathophysiology of several neurodegenerative diseases, including MS, AD, and PD. This review aims to synthesize current research on the role of inflammation in these conditions, emphasizing the potential of inflammatory biomarkers for diagnosis and treatment. We highlight recent findings on the mechanisms of neuroinflammation, the utility of biomarkers in disease differentiation, and the implications for therapeutic strategies. Advances in understanding inflammatory pathways offer promising avenues for developing targeted interventions to improve patient outcomes. Future research should focus on validating these biomarkers in larger cohorts and integrating them into clinical practice to enhance diagnostic accuracy and therapeutic efficacy.

Citing Articles

NLRP3 inflammasome in neuroinflammation and central nervous system diseases.

Xu W, Huang Y, Zhou R Cell Mol Immunol. 2025; .

PMID: 40075143 DOI: 10.1038/s41423-025-01275-w.

Editorial: Neuroinflammatory aspects in neurological disorders.

Alipio P, Fabian L, Jorge G Front Mol Med. 2025; 5:1557546.

PMID: 40012853 PMC: 11850322. DOI: 10.3389/fmmed.2025.1557546.

References

Zagare A, Preciat G, Nickels S, Luo X, Monzel A, Gomez-Giro G . Omics data integration suggests a potential idiopathic Parkinson's disease signature. Commun Biol. 2023; 6(1):1179. PMC: 10662437. DOI: 10.1038/s42003-023-05548-w. View

Mogi M, Harada M, Riederer P, Narabayashi H, Fujita K, Nagatsu T . Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci Lett. 1994; 165(1-2):208-10. DOI: 10.1016/0304-3940(94)90746-3. View

Sevigny J, Chiao P, Bussiere T, Weinreb P, Williams L, Maier M . The antibody aducanumab reduces Aβ plaques in Alzheimer's disease. Nature. 2016; 537(7618):50-6. DOI: 10.1038/nature19323. View

Hodgson L, Li Y, Iturria-Medina Y, Stratton J, Wolf G, Krishnaswamy S . Supervised latent factor modeling isolates cell-type-specific transcriptomic modules that underlie Alzheimer's disease progression. Commun Biol. 2024; 7(1):591. PMC: 11101463. DOI: 10.1038/s42003-024-06273-8. View

Redensek S, Dolzan V, Kunej T . From Genomics to Omics Landscapes of Parkinson's Disease: Revealing the Molecular Mechanisms. OMICS. 2018; 22(1):1-16. PMC: 5784788. DOI: 10.1089/omi.2017.0181. View

Zhang W, Xiao D, Mao Q, Xia H . Role of neuroinflammation in neurodegeneration development. Signal Transduct Target Ther. 2023; 8(1):267. PMC: 10336149. DOI: 10.1038/s41392-023-01486-5. View

Kip E, Parr-Brownlie L . Healthy lifestyles and wellbeing reduce neuroinflammation and prevent neurodegenerative and psychiatric disorders. Front Neurosci. 2023; 17:1092537. PMC: 9975355. DOI: 10.3389/fnins.2023.1092537. View

Lamb Y . Ocrelizumab: A Review in Multiple Sclerosis. Drugs. 2022; 82(3):323-334. PMC: 8862399. DOI: 10.1007/s40265-022-01672-9. View

Kara S, Altunan B, Unal A . Investigation of the peripheral inflammation (neutrophil-lymphocyte ratio) in two neurodegenerative diseases of the central nervous system. Neurol Sci. 2021; 43(3):1799-1807. PMC: 8324446. DOI: 10.1007/s10072-021-05507-5. View

10.

Cossu D, Hatano T, Hattori N . The Role of Immune Dysfunction in Parkinson's Disease Development. Int J Mol Sci. 2023; 24(23). PMC: 10706591. DOI: 10.3390/ijms242316766. View

11.

Heneka M, Golenbock D, Latz E . Innate immunity in Alzheimer's disease. Nat Immunol. 2015; 16(3):229-36. DOI: 10.1038/ni.3102. View

12.

Childs R, Karamacoska D, Lim C, Steiner-Lim G . "Let's talk about sex, inflammaging, and cognition, baby": A meta-analysis and meta-regression of 106 case-control studies on mild cognitive impairment and Alzheimer's disease. Brain Behav Immun Health. 2024; 40:100819. PMC: 11331696. DOI: 10.1016/j.bbih.2024.100819. View

13.

Gonzalez-Ortiz F, Kac P, Brum W, Zetterberg H, Blennow K, Karikari T . Plasma phospho-tau in Alzheimer's disease: towards diagnostic and therapeutic trial applications. Mol Neurodegener. 2023; 18(1):18. PMC: 10022272. DOI: 10.1186/s13024-023-00605-8. View

14.

Dzamko N, Gysbers A, Bandopadhyay R, Bolliger M, Uchino A, Zhao Y . LRRK2 levels and phosphorylation in Parkinson's disease brain and cases with restricted Lewy bodies. Mov Disord. 2016; 32(3):423-432. DOI: 10.1002/mds.26892. View

15.

Hirsch E, Hunot S . Neuroinflammation in Parkinson's disease: a target for neuroprotection?. Lancet Neurol. 2009; 8(4):382-97. DOI: 10.1016/S1474-4422(09)70062-6. View

16.

Arafah A, Khatoon S, Rasool I, Khan A, Rather M, Abujabal K . The Future of Precision Medicine in the Cure of Alzheimer's Disease. Biomedicines. 2023; 11(2). PMC: 9953731. DOI: 10.3390/biomedicines11020335. View

17.

Heppner F, Ransohoff R, Becher B . Immune attack: the role of inflammation in Alzheimer disease. Nat Rev Neurosci. 2015; 16(6):358-72. DOI: 10.1038/nrn3880. View

18.

Singh K, Sethi P, Datta S, Chaudhary J, Kumar S, Jain D . Advances in gene therapy approaches targeting neuro-inflammation in neurodegenerative diseases. Ageing Res Rev. 2024; 98:102321. DOI: 10.1016/j.arr.2024.102321. View

19.

Ning L, Wang B . Neurofilament light chain in blood as a diagnostic and predictive biomarker for multiple sclerosis: A systematic review and meta-analysis. PLoS One. 2022; 17(9):e0274565. PMC: 9473405. DOI: 10.1371/journal.pone.0274565. View

20.

Teunissen C, Petzold A, Bennett J, Berven F, Brundin L, Comabella M . A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology. 2009; 73(22):1914-22. PMC: 2839806. DOI: 10.1212/WNL.0b013e3181c47cc2. View